Table 2 Comparison of demographic data, autoantibodies, disease activity parameters, medications, bone mineral density, and modified Sharp scores in active and inactive rheumatoid arthritis patients
RA patients | P | ||
|---|---|---|---|
DAS28 > 3.2 (n = 29) | DAS28 ≤ 3,2 (n = 24) | ||
Age, years, median (min–max) | 47 (26–65) | 43 (29–73) | |
Female, n (%) | 23 (79.3) | 15 (62.5) | 0.176 |
Postmenaposal, n (%) | 12 (52.2) | 4 (26.7) | 0.120 |
DD, months, median (min–max) | 72 (4–400) | 42.0 (3–216) | 0.102 |
RF, positive, n (%) | 19 (65.5) | 16 (66.7) | 0.930 |
CCP, positive, n (%) | 18 (62.1) | 20 (83.3) | 0.087 |
DAP, median (min–max) | |||
DAS28 | 4.9 (3.3–6.4) | 2.5 (1.4–3.2) | < 0.001 |
Tender joint count | 3 (0–11) | 0 (0–2) | < 0.001 |
Swollen joint count | 2 (0–11) | 0 (0–3) | < 0.001 |
PHA | 50 (0–100) | 10 (0–33) | < 0.001 |
EGA | 45 (10–90) | 10 (0–27) | < 0.001 |
VAS-pain | 40 (0–90) | 10 (0–30) | < 0.001 |
ESR, mm/h | 38 (12–76) | 17.5 (3–51) | < 0.001 |
Medication, n (%) | |||
Methotrexate | 12 (41.4) | 10 (41.7) | 0.983 |
Hydroxychloroquine | 15 (53.6) | 13 (46.4) | 0.859 |
Leflunomide | 12 (41.4) | 12 (52.0) | 0.530 |
Sulfasalazine | 3 (10.3) | 3 (12.5) | > 0.99 |
Glucocorticoids | 23 (79.3) | 13 (54.2) | 0.051 |
Anti-TNFα | 5 (17.2) | 2 (8.3) | 0.340 |
Tofacitinib | 2 (6.9) | 2 (8.3) | > 0.99 |
Tocilizumab | 1 (3.4) | 1 (4.2) | > 0.99 |
Rituximab | 1 (3.4) | 0 (0) | > 0.99 |
BMD, gr/cm2, mean ± SD | |||
Femur | 0.9 ± 0.1 | 0.9 ± 0.1 | 0.809 |
Lombar vertebra | 0.9 ± 0.2 | 0.9 ± 0.2 | 0.586 |
Modified Sharp total score, median (min–max) | |||
Observer-1 | 27 (0–220) | 20 (0–64) | 0.136 |
Observer-2 | 26 (0–218) | 21 (0–65) | 0.129 |